$0.04
(Market cap
$2,213 Mln
Recently Viewed
Clear AllMarket cap
$2,213 Mln
Revenue (TTM)
$175 Mln
P/E Ratio
--
P/B Ratio
7
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-49 Mln
ROE
-0.5 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-4.5
Debt to Equity
0
Book Value
$--
EPS
$-2.2
Face value
--
Shares outstanding
86,476,000
CFO
$-1,089.21 Mln
EBITDA
$-1,337.26 Mln
Net Profit
$-1,324.59 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Deciphera Pharmaceuticals LLC (DCPH)
| 58.8 | 0.9 | 51.2 | 82.7 | -8.9 | 3.2 | -- |
|
BSE Sensex*
| -6.4 | 6.4 | -3.5 | 0.9 | 10.0 | 10.7 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|
|
Deciphera Pharmaceuticals LLC (DCPH)
| -1.6 | 67.8 | -82.9 | -8.3 | 196.5 | -7.4 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Deciphera Pharmaceuticals LLC (DCPH)
|
25.6 | 2,212.9 | 174.9 | -190.4 | -118.4 | -54.6 | -- | 7.0 |
| 0.1 | 3.6 | 0.3 | -95.1 | -21,828.5 | -265.1 | -- | 0.3 | |
| 2.1 | 6.0 | 0.1 | -6.2 | -15,087.2 | -15.2 | -- | 1.9 | |
| 22.9 | 71.7 | 0.0 | -24.8 | -- | -81.5 | -- | 2.1 |
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the... United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. As of June 11, 2024, Deciphera Pharmaceuticals, Inc. operates as a subsidiary of Ono Pharmaceutical Co., Ltd. Read more
President, CEO & Director
Mr. Steven L. Hoerter
President, CEO & Director
Mr. Steven L. Hoerter
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Deciphera Pharmaceuticals LLC (DCPH) is $25.61 (NASDAQ) as of 10-Jun-2024 16:09 EDT. Deciphera Pharmaceuticals LLC (DCPH) has given a return of -8.9% in the last 3 years.
Since, TTM earnings of Deciphera Pharmaceuticals LLC (DCPH) is negative, P/E ratio is not available.
The P/B ratio of Deciphera Pharmaceuticals LLC (DCPH) is 7.00 times as on 10-Jun-2024, a 53 premium to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-7.03
|
3.91
|
|
2022
|
-6.96
|
3.65
|
|
2021
|
-1.91
|
1.86
|
|
2020
|
-11.99
|
5.88
|
|
2019
|
-13.98
|
4.90
|
The 52-week high and low of Deciphera Pharmaceuticals LLC (DCPH) are Rs -- and Rs -- as of 21-Apr-2026.
Deciphera Pharmaceuticals LLC (DCPH) has a market capitalisation of $ 2,213 Mln as on 10-Jun-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Deciphera Pharmaceuticals LLC (DCPH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.